Journal Information
ISSN / EISSN : 0021-9150 / 1879-1484
Current Publisher: Elsevier BV (10.1016)
Former Publisher: Wiley (10.1002)
Total articles ≅ 29,540
Current Coverage
Archived in

Latest articles in this journal

Daniel Mrak, Bernhard Zierfuss, Clemens Höbaus , Carsten Thilo Herz, Gerfried Pesau, Gerit-Holger Schernthaner
Published: 1 January 2021
Atherosclerosis, Volume 317, pp 41-46; doi:10.1016/j.atherosclerosis.2020.11.026

Background and aimsThe TNF-superfamily member sTWEAK and its scavenger receptor sCD163 are potentially involved in pathophysiological processes of atherosclerosis. In patients with peripheral arterial disease, previous research has shown that sTWEAK and the sCD163/sTWEAK ratio were independently associated with long term all-cause and cardiovascular survival. Since previous investigations emphasized on symptomatic peripheral arterial disease including critical limb ischemia, this study evaluates sTWEAK and sCD163 in a cohort of stable peripheral arterial disease including asymptomatic (Fontaine stage I) and intermittent claudication (Fontaine stage II) patients.MethodssTWEAK concentrations of 354 patients were measured using a commercially available ELISA kit. sCD163 was quantified using a multiplex bead assay. Cox proportional hazards regression was used to assess outcome after a seven-year follow-up. Hazard ratios are given as interquartile range.ResultsPatients with intermittent claudication exhibited increased sCD163 levels in comparison to asymptomatic patients (p = 0.002). However, sTWEAK was not related to peripheral arterial disease severity (p = 0.740). A multivariable Cox-proportional hazard models including sTWEAK and cardiovascular risk factors (age, HbA1c, CRP, LDL-C, BMI, eGFR) revealed an inverse association with all-cause mortality (HR 0.775 (95% CI 0.623–0.965) and cardiovascular mortality (HR 0.710 (95% CI 0.534–0.944)). Further multivariable models including sCD163 or the sCD163/sTWEAK ratio and cardiovascular risk factors showed no association with mortality.ConclusionsThis study highlights the use of sCD163 as a novel biomarker for PAD severity and supports sTWEAK as an independent predictor of all-cause and cardiovascular mortality even in stable peripheral arterial disease.
Mira Haapala, Leo-Pekka Lyytikäinen, Mikko Peltokangas , Teemu Koivistoinen, Nina Hutri-Kähönen, Mika-Matti Laurila, Matti Mäntysalo, Olli T. Raitakari, Mika Kähönen, Terho Lehtimäki, et al.
Published: 1 January 2021
Atherosclerosis; doi:10.1016/j.atherosclerosis.2021.01.006

Azin Kheirkhah, Claudia Lamina, Barbara Rantner, Barbara Kollerits, Marietta Stadler, Johannes Pohlhammer, Peter Klein-Weigel, Gustav Fraedrich, Florian Kronenberg
Published: 1 January 2021
Atherosclerosis, Volume 316, pp 41-47; doi:10.1016/j.atherosclerosis.2020.11.025

Background and aimsPeripheral artery disease (PAD) affects more than 200 million people worldwide. Increased low-density lipoprotein cholesterol (LDL-C)levels are a risk factor for PAD and the concentrations are influenced by proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 regulates the recycling of the LDL receptors to the cell membrane surface. Only a limited number of mostly small studies investigated the association between serum PCSK9 concentrations and PAD of different definition, which revealed contrasting results.MethodsSerum PCSK9, lipoprotein(a) [Lp(a)] and other lipoprotein concentrations were measured in male participants of the CAVASIC study, a case-control study of 248 patients with intermittent claudication and 251 age and diabetes-matched controls.ResultsPAD patients had significantly higher PCSK9 concentrations when compared to controls (250 ± 77 vs. 222 ± 68 ng/mL, p < 0.001). Logistic regression analysis with adjustment for age revealed that an increase in PCSK9 concentrations of 100 ng/mL was associated with a 1.78-fold higher risk for PAD (95%CI 1.38–2.33, p = 1.43 × 10−5). The association attenuated, but was still significant when adjusting additionally for age, Lp(a)-corrected LDL cholesterol, HDL cholesterol, high-sensitivity-CRP, statin treatment, hypertension, diabetes mellitus and smoking (OR = 1.49, 95%CI 1.03–2.18, p = 0.035). The strongest association was observed when both PCSK9 concentrations were above the median and Lp(a) concentrations were above 30 mg/dL (OR = 3.35, 95%CI 1.49–7.71, p = 0.0038).ConclusionsOur findings suggest an association of higher PCSK9 concentrations with PAD, which was independent of other lipid parameters and classical cardiovascular risk factors.
Tomonari Koike , Yui Koike, Dongshan Yang, Yanhong Guo, Oren Rom, Jun Song, Jie Xu, Y Eugene Chen , Yanli Wang, Tianqing Zhu, et al.
Published: 1 January 2021
Atherosclerosis, Volume 316, pp 32-40; doi:10.1016/j.atherosclerosis.2020.11.028

The publisher has not yet granted permission to display this abstract.
Johann Auer , Lisa Auer
Published: 1 January 2021
Atherosclerosis, Volume 316, pp 66-68; doi:10.1016/j.atherosclerosis.2020.10.889

Victoria Marco-Benedí, Martín Laclaustra , Ana M. Bea, Manuel Suarez-Tembra, Núria Plana, Xavier Pinto, Angel Brea, Rosa Sanchez-Hernandez, Fernando Civeira
Published: 1 January 2021
Atherosclerosis; doi:10.1016/j.atherosclerosis.2021.01.015

The publisher has not yet granted permission to display this abstract.
Published: 1 January 2021
Atherosclerosis, Volume 316; doi:10.1016/s0021-9150(20)31579-3

Jiqing Li, Zhentang Zhang, Shucheng Si, Bojie Wang, Fuzhong Xue
Published: 1 January 2021
Atherosclerosis; doi:10.1016/j.atherosclerosis.2021.01.005

Zhongzhao Teng , Shuo Wang, Aziz Tokgoz, Valentina Taviani, Joseph Bird , Umar Sadat, Yuan Huang , Andrew J. Patterson, Nichola Figg, Martin J. Graves, et al.
Published: 1 January 2021
Atherosclerosis; doi:10.1016/j.atherosclerosis.2021.01.017

The publisher has not yet granted permission to display this abstract.
Back to Top Top